“SALT LAKE CITY, Aug. 22, 2023 (GLOBE NEWSWIRE) — Brace for Impact: Myriad Genetics, the Vanguard of Genetic Exploration, and Onsite Women’s Health, Champions of Breast Wellness, Unite to Illuminate the Path to Breast Cancer Awareness.”
In an electrifying alliance, Myriad Genetics, the torchbearer of genetic testing and precision medicine, teams up with Onsite Women’s Health, heralded nationwide for their breast health prowess. Together, they unveil a groundbreaking venture – a beacon of hope in the realm of breast cancer risk understanding.
Imagine a symphony where Myriad’s cutting-edge MyRisk® with RiskScore® marries the expertise of Onsite Women’s Health, masters of mammography and breast ultrasound. The result? A revelation of personalized insights that elevate clinical care to unforeseen heights, embracing the over 400,000 patients embraced by Onsite’s wings across the nation.
This partnership doesn’t merely stop at knowledge; it extends its arms to younger patients who are on the precipice of breast cancer risk. The collaboration champions the American College of Radiology and the Society of Breast Imaging’s call to evaluate breast cancer risk by the age of 30, a shield against a looming adversary. And it doesn’t end there. For high-risk women, the dance continues with the rhythm of annual screening breast MRI and mammography.
In the words of Paul Diaz, the maestro behind Myriad Genetics, “Nearly one in four unaffected women meet hereditary cancer testing criteria.” The collaboration opens doors to the 25% of deserving women, providing them with access to the treasure trove of genetic testing and risk assessment. It’s a lifeline that stretches toward risk reduction and early detection, a symphony of hope painted with the brush of personalized medicine.
Brian Marger, the visionary at Onsite Women’s Health, paints a picture of synergy: “Myriad’s prowess in precision medicine aligns seamlessly with our commitment to personalization.” It’s a melody of expertise, innovation, and a common goal – to grasp the essence of each woman’s unique risk and catch cancer while it’s most vulnerable.
This isn’t just an announcement; it’s a crescendo of change. One-third of Onsite’s OBGYN and primary care physician partnerships will soon be in the fold, with the anthem echoing even louder in 2024. As the stage is set, applause isn’t just welcomed; it’s anticipated.
About Myriad Genetics
Myriad Genetics stands at the forefront of genetic testing and precision medicine, passionately committed to enhancing the health and vitality of everyone. With innovation as our compass, we craft genetic tests that unveil the tapestry of disease risks and progression, illuminating pathways for informed treatment choices across diverse medical realms. Through harnessing genetic insights, we not only elevate patient care but also drive down the veils of healthcare expenses.
About Onsite Women’s Health
In dynamic collaboration with visionary healthcare partners nationwide, Onsite Women’s Health unfolds a realm of all-encompassing breast imaging services. From the captivating depth of 3D screening mammography to the innovative embrace of automated screening breast ultrasound, our canvas spans diagnostic mammography, ultrasound, and a lifelong dance with breast cancer risk assessment.
Rooted in a mission to safeguard more lives through early cancer revelation, Onsite orchestrates a symphony of compliance and detection, drawing women closer to the heartbeat of accessible mammography. We curate a harmonious alliance with breast-focused radiologists, marrying their expertise with cutting-edge AI-powered technology that resonates in every corner of the market. Infused with AI’s brilliance, we transform risk assessment into an art, painting bespoke care journeys based on individual profiles.
In the tapestry of healthcare, Onsite stitches patient satisfaction, enhanced breast well-being, and an added flourish of revenue for our practice partners. From our inception in 2008, we’ve choreographed over two million examinations across 26 states, an ode to our commitment to unraveling health’s most intricate mysteries.
Safe Harbor Statement
Embarking on a journey toward the horizon of innovation, this press release weaves a tapestry of “forward-looking statements,” igniting the spirit of anticipation in accordance with the Private Securities Litigation Reform Act of 1995. Imagine a canvas adorned with promises of a groundbreaking breast cancer risk assessment program, a beacon that amplifies genetic testing accessibility while unveiling the secrets of younger patients susceptible to breast cancer’s embrace.
This symphony of progress unfurls as Onsite’s masterpiece, destined to grace the realms of one third of our cherished OBGYN and PCP partnerships in the imminent months, with a grand crescendo poised for 2024. Anchored in the present yet reaching toward tomorrow, these “forward-looking statements” are the brushstrokes of management’s foresight, dancing in harmony with uncertainties that cast their shadows.
From the alluring unknowns to the documented risks etched within the U.S. Securities and Exchange Commission’s archives, including the poignant chapters of our Annual Report on Form 10-K from March 1, 2023, and the chapters yet to be written in the Quarterly Reports on Form 10-Q or Current Reports on Form 8-K, we navigate this adventure without obligation, save for the duty to illuminate truth. The chronicle of Myriad’s voyage is etched on these pages, a testament to our commitment to kindle the fires of tomorrow while respecting the laws that govern our path.